Optimizing long-acting PrEP and opioid treatment for people in jails and prisons
Official title: NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings
Funded at Duke University · NIH-11565766 · Data updated 2026-11-12
This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $149,764 |
| NIH project number | 3R33DA060583-03S1 |
| Project ID | NIH-11565766 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with opioid use disorder and/or HIV risk factors who are incarcerated and eligible for PrEP and MOUD in selected correctional settings or during reentry.
✕Less likely to help
Individuals without OUD or HIV risk, or those not in correctional settings or post-release care pathways, may see no direct benefit.
What this research studies
People in correctional settings face high HIV risk and opioid use disorders. The study will create and test a delivery protocol for long-acting injectable PrEP plus long-acting buprenorphine, and compare it with the standard oral PrEP and sublingual buprenorphine. It uses a hybrid implementation-effectiveness design to see how well the approach works in prison and after release in Maryland and Washington, DC. The goal is to find scalable practices that keep people engaged in treatment and reduce HIV risk and opioid-related harms. Researchers will measure how easily clinics can implement the approach and whether outcomes improve compared with current care.
Why it matters
Potential benefit: If successful, this could lead to more consistent HIV prevention and opioid treatment for incarcerated individuals, reducing HIV transmission and improving health after release.
How similar studies have gone: Prior work suggests that long-acting PrEP and MOUD can improve adherence; this study tests a combined, packaged approach in a high-need setting.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Brinkley-Rubinstein, Lauren — Duke University
- Study coordinator: Brinkley-Rubinstein, Lauren
Related research
Other NIH-funded projects on the same topics.
-
Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)
A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.
-
Precise epigenetic drugs for opioid addiction
A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.
-
Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans
This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.
-
Scaling up medications for opioid use disorder in residential treatment programs
This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.
-
Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN
This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.
-
Multimodal fetal and placental imaging to predict outcomes in infants exposed to opioids
This project uses brain and placenta imaging plus biomarkers to understand how prenatal opioid exposure affects babies and how to predict and improve outcomes for infants born to mothers with opioid use disorder.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.